Vaccine: FluMist
Company: MedImmune
Approval Date: June 20
Protects Against: Influenza

MedImmune, maker of the nasal spray influenza vaccine FluMist, entered the 2012-2013 flu season well-prepared; the company says it has 620,000 extra doses on hand during a time when flu vaccines are in demand and running low. Approved for individuals ages 2 to 49, the vaccine first entered the market in 2003. The spray vaccine differs from its needle-delivered counterparts in that it allows patients to avoid a painful or uncomfortable shot. In 2012, FluMist sales hit an estimated $162 million.

In May 2012, MedImmune teamed with Hemispherx Biopharma ($HEB) to test that company's RNA-based adjuvant, Ampligen, intranasally in combination with FluMist. Preclinical research conducted in Japan showed that Ampligen could amplify immune response to influenza vaccines.

For more:
Special Report: Top 10 selling flu vaccines of 2012
Ampligen-FluMist nasal trial begins
Vaccine maker MedImmune has a new AZ chief
AstraZeneca's FluMist Quadrivalent to hit U.S. market


Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.